Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Graves Ophthalmopathy: early-phase trial registry
3 of 4 indexed Graves Ophthalmopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Graves Ophthalmopathy: 4 US clinical trials tracked, 3 recruiting.
Graves Ophthalmopathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Sling Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition graves-ophthalmopathy
OPEN 3 | RECR 75% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Graves Ophthalmopathy lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Graves Ophthalmopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Graves Ophthalmopathy is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Walter Reed National Military Medical Center
NCT06275373
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT06112340
Bimatoprost as a Treatment for Graves' Orbitopathy
Johns Hopkins University
NCT03708627
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT05276063
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Graves Ophthalmopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Graves Ophthalmopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Graves Ophthalmopathy page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Graves Ophthalmopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sling Therapeutics sponsors the most Graves Ophthalmopathy trials on record, review their full trial history before evaluating a specific study. See Sling Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Graves Ophthalmopathy condition card totals 4 registered trials; most-linked intervention Linsitinib; top US site state West Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.